These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 8471072

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
    Aherne GW, Hardcastle A, Valenti M, Bryant A, Rogers P, Pettit GR, Srirangam JK, Kelland LR.
    Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796
    [Abstract] [Full Text] [Related]

  • 24. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.
    Verdier-Pinard P, Kepler JA, Pettit GR, Hamel E.
    Mol Pharmacol; 2000 Jan; 57(1):180-7. PubMed ID: 10617693
    [Abstract] [Full Text] [Related]

  • 25. Antineoplastic agents 360. Synthesis and cancer cell growth inhibitory studies of dolastatin 15 structural modifications.
    Pettit GR, Flahive EJ, Boyd MR, Bai R, Hamel E, Pettit RK, Schmidt JM.
    Anticancer Drug Des; 1998 Jan; 13(1):47-66. PubMed ID: 9474242
    [Abstract] [Full Text] [Related]

  • 26. Interaction of dolastatin 10 with bovine brain tubulin.
    Ludueña RF, Roach MC, Prasad V, Pettit GR.
    Biochem Pharmacol; 1992 Feb 04; 43(3):539-43. PubMed ID: 1540211
    [Abstract] [Full Text] [Related]

  • 27. Synthesis and X-ray crystal structure of the dolabellaauricularia peptide dolastatin 18.
    Pettit GR, Hogan F, Herald DL.
    J Org Chem; 2004 Jun 11; 69(12):4019-22. PubMed ID: 15176826
    [Abstract] [Full Text] [Related]

  • 28. Effects of antimitotic agents on tubulin-nucleotide interactions.
    Correia JJ.
    Pharmacol Ther; 1991 Nov 11; 52(2):127-47. PubMed ID: 1818332
    [Abstract] [Full Text] [Related]

  • 29. The molecular pharmacology of symplostatin 1: a new antimitotic dolastatin 10 analog.
    Mooberry SL, Leal RM, Tinley TL, Luesch H, Moore RE, Corbett TH.
    Int J Cancer; 2003 Apr 20; 104(4):512-21. PubMed ID: 12584751
    [Abstract] [Full Text] [Related]

  • 30. LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis.
    de Arruda M, Cocchiaro CA, Nelson CM, Grinnell CM, Janssen B, Haupt A, Barlozzari T.
    Cancer Res; 1995 Jul 15; 55(14):3085-92. PubMed ID: 7606731
    [Abstract] [Full Text] [Related]

  • 31. Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin.
    Smith CD, Zhang X.
    J Biol Chem; 1996 Mar 15; 271(11):6192-8. PubMed ID: 8626409
    [Abstract] [Full Text] [Related]

  • 32. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc.
    Turner T, Jackson WH, Pettit GR, Wells A, Kraft AS.
    Prostate; 1998 Feb 15; 34(3):175-81. PubMed ID: 9492845
    [Abstract] [Full Text] [Related]

  • 33. Dolastatin 11, a marine depsipeptide, arrests cells at cytokinesis and induces hyperpolymerization of purified actin.
    Bai R, Verdier-Pinard P, Gangwar S, Stessman CC, McClure KJ, Sausville EA, Pettit GR, Bates RB, Hamel E.
    Mol Pharmacol; 2001 Mar 15; 59(3):462-9. PubMed ID: 11179440
    [Abstract] [Full Text] [Related]

  • 34. Interaction of cryptophycin 1 with tubulin and microtubules.
    Kerksiek K, Mejillano MR, Schwartz RE, Georg GI, Himes RH.
    FEBS Lett; 1995 Dec 11; 377(1):59-61. PubMed ID: 8543019
    [Abstract] [Full Text] [Related]

  • 35. Characterization of the interaction of cryptophycin 1 with tubulin: binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction.
    Bai R, Schwartz RE, Kepler JA, Pettit GR, Hamel E.
    Cancer Res; 1996 Oct 01; 56(19):4398-406. PubMed ID: 8813133
    [Abstract] [Full Text] [Related]

  • 36. Synthesis and antiproliferative activity of a cyclic analog of dolastatin 10.
    Poncet J, Hortala L, Busquet M, Guéritte-Voegelein F, Thoret S, Pierré A, Atassi G, Jouin P.
    Bioorg Med Chem Lett; 1998 Oct 20; 8(20):2855-8. PubMed ID: 9873636
    [Abstract] [Full Text] [Related]

  • 37. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15.
    Beckwith M, Urba WJ, Longo DL.
    J Natl Cancer Inst; 1993 Mar 17; 85(6):483-8. PubMed ID: 8445676
    [Abstract] [Full Text] [Related]

  • 38. Differential effects of ethyl 5-amino-2-methyl-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl carbamate analogs modified at position C2 on tubulin polymerization, binding, and conformational changes.
    Barbier P, Peyrot V, Sarrazin M, Rener GA, Briand C.
    Biochemistry; 1995 Dec 26; 34(51):16821-9. PubMed ID: 8527458
    [Abstract] [Full Text] [Related]

  • 39. The dolastatins, a family of promising antineoplastic agents.
    Poncet J.
    Curr Pharm Des; 1999 Mar 26; 5(3):139-62. PubMed ID: 10066887
    [Abstract] [Full Text] [Related]

  • 40. Synthesis and antitumor activity of novel dolastatin 10 analogs.
    Miyazaki K, Kobayashi M, Natsume T, Gondo M, Mikami T, Sakakibara K, Tsukagoshi S.
    Chem Pharm Bull (Tokyo); 1995 Oct 26; 43(10):1706-18. PubMed ID: 8536345
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.